Objectif du module : Identifier un triple emballage, définir les termes utilisés pour les emballages,classer les matières infectieuses et les exigences d'emballage correspondante
Objectif du module : Identifier un accident d'exposition au sang, les conduites à risque, la conduite à tenir, les mesures de précautions universelles.
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.more
This document describes recommended measures for dealing with medical and other staff employed either in patient care or in outbreak control during the 2014 Ebola outbreak.
This document builds on the Background document prepared for the September 4-5, 2014 Consultation. It includes proposed elements to consider during the development of a framework to assist decision-making at global and national level.
The aim of the document is to assist Member States and releva...nt partners in their discussions to identify the best approaches to ensure the accelerated evaluation and use of available or near-term therapies and vaccines for the treatment and prevention of EVD. The document calls for a coordinated effort by the international community to remove unnecessary obstacles towards this goal.more
The Blueprint is intended to guide programming, resource allocation, and commitments to achieve the national objective of a contraceptive prevalence rate (CPR) of 36 percent by 2018.